AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
Item8.01. Other Events.
The senior management of Amicus Therapeutics,Inc. (the Company)
is using the presentations attached as Exhibit99.1 and
Exhibit99.2 to this Current Report in its current meetings with
investors and analysts.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits: The ExhibitIndex annexed hereto is incorporated
herein by reference.
|
Exhibit No. |
|
Description |
|
99.1 |
Presentation Materials Corporate Overview (February2017) |
|
|
99.2 |
Presentation Materials Pompe Disease: A New Understanding |
About AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability. AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Recent Trading Information
AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) closed its last trading session down -0.03 at 6.05 with 2,828,567 shares trading hands.